Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia
Journal of Medicinal Chemistry2013Vol. 56(19), pp. 7590–7607
Citations Over TimeTop 10% of 2013 papers
Claudia Betschart, Samuel Hintermann, Dirk Behnke, Simona Cotesta, Markus Fendt, Christine E. Gee, Laura H. Jacobson, Grit Laue, Silvio Ofner, Vinod D. Chaudhari, Sangamesh Badiger, Chetan Pandit, Juergen Wagner, Daniël Hoyer
Abstract
Dual orexin receptor (OXR) antagonists (DORAs) such as almorexant, 1 (SB-649868), or suvorexant have shown promise for the treatment of insomnias and sleep disorders in several recent clinical trials in volunteers and primary insomnia patients. The relative contribution of antagonism of OX1R and OX2R for sleep induction is still a matter of debate. We therefore initiated a drug discovery project with the aim of creating both OX2R selective antagonists and DORAs. Here we report that the OX2R selective antagonist 26 induced sleep in mice primarily by increasing NREM sleep, whereas the DORA suvorexant induced sleep largely by increasing REM sleep. Thus, OX2R selective antagonists may also be beneficial for the treatment of insomnia.
Related Papers
- → Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?(2013)111 cited
- → Structure–Activity Relationship, Biological, and Pharmacological Characterization of the Proline Sulfonamide ACT‐462206: a Potent, Brain‐Penetrant Dual Orexin 1/Orexin 2 Receptor Antagonist(2014)40 cited
- → Role of the orexin (hypocretin) system in contextual fear conditioning in rats(2016)28 cited
- → Doxepin in the treatment of primary insomnia — A placebo-controlled, double-blind, polysomnographic study(2000)19 cited
- Orexin Receptor Antagonists: a Promising Approach to the Treatment of Insomnia(2014)